Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Jun 3, 2022
Date Accepted: Feb 7, 2024

The final, peer-reviewed published version of this preprint can be found here:

The Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study

Mylle S, Papeleu J, Hoorens I, Verhaeghe E, Brochez L

The Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study

JMIR Dermatol 2024;7:e40053

DOI: 10.2196/40053

PMID: 38422495

PMCID: 10940973

The Value of Teledermatology Advice For Skin Toxicity in Oncology: Experience From a Pilot Study

  • Sofie Mylle; 
  • Jorien Papeleu; 
  • Isabelle Hoorens; 
  • Evelien Verhaeghe; 
  • Lieve Brochez

ABSTRACT

Despite skin toxicity during anti-EGFR therapy occurs frequently and significantly impacts patients’ quality of life, it is often not recognized nor optimally managed. This may lead to unnecessary dose reductions or treatment discontinuations of the cancer treatment. Access to rapid dermatology advice may be limited in hospitals. In this multicenter pilot study, we conclude that teledermatology may add value for both patients and oncologists in the management of treatment-induced skin toxicity.


 Citation

Please cite as:

Mylle S, Papeleu J, Hoorens I, Verhaeghe E, Brochez L

The Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study

JMIR Dermatol 2024;7:e40053

DOI: 10.2196/40053

PMID: 38422495

PMCID: 10940973

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.